| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
The target of anti-TB agent 1 is not specified in the provided search results. It is a potent anti-tuberculosis agent, but its mechanism of action is not described. Its target is likely a protein essential for the survival of Mycobacterium tuberculosis.
|
|---|---|
| ln Vitro |
In cell-free systems, the activity of anti-TB agent 1 could be assessed by its ability to inhibit its target enzyme or by its binding affinity. However, the specific target is not known, so such assays are not described. In vitro, anti-TB agent 1 exhibits potent antibacterial activity against Mycobacterium tuberculosis H37Rv, with exceptionally low MIC values of less than 0.002 µg/ml for both standard and resistant strains. This demonstrates its high potency.
|
| ln Vivo |
In vivo, anti-TB agent 1 is an orally active anti-tuberculosis agent. Its efficacy in animal models of tuberculosis is implied by its designation as an "anti-TB agent," but specific data is not provided.
|
| Enzyme Assay |
The antibacterial activity of anti-TB agent 1 is tested in vitro using standardized susceptibility testing methods against M. tuberculosis. The minimum inhibitory concentration (MIC) is determined using broth microdilution methods.
|
| Cell Assay |
Cell-based assays for anti-TB agent 1 involve infecting macrophages with M. tuberculosis and treating them with the compound. The reduction in intracellular bacterial load is measured to assess its efficacy.
|
| Animal Protocol |
In vivo efficacy is evaluated in animal models of tuberculosis, such as the mouse aerosol infection model. Animals are infected with M. tuberculosis and treated with the compound orally. The reduction in bacterial burden in the lungs is measured.
|
| ADME/Pharmacokinetics |
anti-TB agent 1 is orally active, suggesting it is absorbed from the gastrointestinal tract. Its pharmacokinetic properties, such as bioavailability, half-life, and tissue distribution, are likely being characterized in preclinical studies.
|
| Toxicity/Toxicokinetics |
Toxicological data for anti-TB agent 1 is not provided in the search results. As a potent antibacterial agent, its safety profile is an important consideration for its development. It is intended for research use.
|
| Additional Infomation |
anti-TB agent 1 is a research compound with potent anti-tuberculosis activity. It is a valuable tool for studying tuberculosis and for developing new treatments. It is not an approved drug and is for research use only.
|
| Molecular Formula |
C23H19F3N4O3
|
|---|---|
| Molecular Weight |
456.42
|
| Exact Mass |
456.14
|
| CAS # |
2294013-78-6
|
| PubChem CID |
138377595
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
4
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
33
|
| Complexity |
659
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=NN2C=CC(=CC2=C1C(=O)NCC3=NC=C(C=C3)C4=CC=C(C=C4)OC(F)(F)F)OC
|
| InChi Key |
FJXCWOFMPQOVBV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H19F3N4O3/c1-14-21(20-11-19(32-2)9-10-30(20)29-14)22(31)28-13-17-6-3-16(12-27-17)15-4-7-18(8-5-15)33-23(24,25)26/h3-12H,13H2,1-2H3,(H,28,31)
|
| Chemical Name |
5-methoxy-2-methyl-N-[[5-[4-(trifluoromethoxy)phenyl]pyridin-2-yl]methyl]pyrazolo[1,5-a]pyridine-3-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1910 mL | 10.9548 mL | 21.9096 mL | |
| 5 mM | 0.4382 mL | 2.1910 mL | 4.3819 mL | |
| 10 mM | 0.2191 mL | 1.0955 mL | 2.1910 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
